PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS
OBJECTIVES: I. Evaluate the efficacy of myeloablative total-body irradiation and etoposide
followed by autologous peripheral blood stem cell (PBSC) transplantation in prolonging the
disease-free survival of patients with acute leukemia. II. Investigate the ability of growth
factor-primed PBSC to provide hematopoietic reconstitution following myeloablative therapy.
OUTLINE: Patients are treated on Regimen A, then Regimen B. Regimen A: Stem Cell
Mobilization. Granulocyte Colony Stimulating Factor (Amgen), G-CSF, NSC-614629. Regimen B:
Radiotherapy and Myeloablative Chemotherapy with Hematopoietic Rescue. Total-Body
Irradiation, TBI (high-energy electrons used for lung boost); and Etoposide, VP-16,
NSC-141540; with Peripheral Blood Stem Cells, PBSC; G-CSF.
PROJECTED ACCRUAL: Up to 45 patients will be studied over approximately 3 years.
Primary Purpose: Treatment
Peter Maslak, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|